Drug Profile
Levodopa/carbidopa subcutaneous - NeuroDerm
Alternative Names: Carbidopa/levodopa subcutaneous - NeuroDerm; ND-0612; ND-0612H; ND-0612L; ND-0680Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator NeuroDerm
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Parkinson's disease
Most Recent Events
- 04 Mar 2024 Preregistration for Parkinson's disease in USA (SC)
- 04 Mar 2024 FDA assigns PDUFA action date of second quarter 2024 for Levodopa/carbidopa subcutaneous for Parkinson's disease
- 22 Apr 2023 Adverse events and efficacy data from the phase III BouNDless trial in Parkinson's disease presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)